ALSEN — Sensorion SA Share News
0.000.00%
Last trade - 00:00Brief: Sensorion Reschedules General Assembly To May 20
Brief: Sensorion FY Net Loss Narrows To 12.1 Million Euros
Brief: Sensorion Provides Update On SENS-401 SSNHL Phase 2 AUDIBLE-S Trial Enrollment
Brief: Sensorion Appoints Dr Geraldine Honnet As Chief Medical Officer
Brief: Sensorion To Include Military Sites In Sens-401 Phase 2 Study
Brief: Sensorion Announces Full Conversion Of Sofinnova Partners Convertible Bonds Into Ordinary Shares
Brief: Sensorion Announces Full Conversion Of Invus Convertible Bonds Into Ordinary Shares
Brief: Sensorion Presents New SENS-401 Preclinical Data
Brief: Sensorion Announces Positive Data Safety Monitoring Board Review Of Phase 2 Trial For SENS-401
Brief: Sensorion Announces 5.6 Million Euros Non-Dilutive Funding To Support SENS-401 Phase 2 Study
Brief: Sensorion SENS-111 Fails To Meet Clinical Endpoint In Phase 2b Trial
Brief: Sensorion Announces Results Of New Sens-401 Preclinical Data
Brief: Sensorion H1 Net Loss Narrows To 5.5 Million Euros
Brief: Sensorion Announces Last Visit In SENS-111 Phase 2 Clinical Trial
Brief: Sensorion Announces Two Presentations At AAO-HNSF 2019 In New Orleans
Brief: Sensorion Appoints John Furey As Independent Board Member
Brief: Sensorion Receives FDA IND Approval For Arazasetron (Sens-401)
Brief: Sensorion Receives European Medicines Agency Agreement On Pediatric Investigation Plan For Arazasetron In Two Indications
Brief: Sensorion Announces EUR 20 MLN Convertible Bond Issue